Download PDF
Pharmacopsychiatry 2001; 34(Suppl1): 89-97
DOI: 10.1055/s-2001-15449
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Effects of Hypericum perforatum (St. John’s wort) on Passive Avoidance in the Rat: Evaluation of Potential Neurochemical Mechanisms Underlying its Antidepressant Activity

I. Misane1,2 , S. O. Ögren1
  • 1Division of Behavioral Neuroscience, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
  • 2Department of Molecular Neuroendocrinology, Max Planck Institute for Experimental Medicine, Goettingen, Germany
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Along with traditional pharmacotherapies, extracts of Hypericum perforatum L. (St. John’s wort) are used in the treatment of mild to moderately severe depression. Hypericum is a nonspecific inhibitor of the neuronal uptake of monoamines (serotonin, 5-HT; noradrenaline, NA; dopamine, DA) as well as GABA and glutamate. Hypericum extracts have been shown to be active in several different “animal models for antidepressant drugs”. As one of a large number of chemical constituents, the phoroglucinol derivative hyperforin might be an important “antidepressant component”” of hypericum. However, the exact role of neurochemical mechanisms underlying in vivo actions of hypericum and hyperforin are not well defined. In the present study, we compared the effects of hypericum, hyperforin and hyperforin-free hypericum and the three conventional antidepressants paroxetine, imipramine and desipramine using the passive avoidance (PA) task in the rat. The 5-HT-releasing compound p-chloroamphetamine (PCA), which operates through the 5-HT neuronal transporter, was used to reveal the potential in vivo effects on 5-HT uptake mechanisms. To examine the ability of the test-compounds to enhance noradrenaline (NA) transmission in vivo, subeffective doses of scopolamine were used. Taken together, our results suggest that (1) hypericum given at high doses can probably affect the neuronal 5-HT uptake mechanisms in a manner more reminiscent of TCAs than SSRIs; (2) similar to TCAs and SSRIs, hypericum and hyperforin are active in the scopolamine test. Hyperforin appears to play a major role in the action of hypericum in this model. Both 5-HT and NA might concomitantly contribute to the effects of different antidepressants in the “low-dose scopolamine” model; (3) hypericum might enhance both 5-HT and NA transmission in forebrain limbic brain circuits important for mood control, which could underly its antidepressant effects. However, the relative contribution of different constituents and exact mechanisms of action require further evaluation.

References

  • 1 Ambrogi Lorenzini C G, Baldi E, Bucherelli C, Sacchetti B, Tassoni G. Analysis of mnemonic processing by means of totally reversible neural inactivations.  Brain Res Brain Res Protoc. 1997;  1 391-398
    CrossrefPubMedGoogle Scholar
  • 2 Axt K J, Molliver M E, Qian Y, Blakely R D. Subtypes of 5-HT axons differ in their expression of serotonin transporter.  Soc Neurosci Abstr. 1995;  21 865
    PubMedGoogle Scholar
  • 3 Banerjee S P, Kung L S, Riggi S J, Chanda S K. Development of beta-adrenergic receptor subsensitivity by antidepressants.  Nature. 1977;  268 455-456
    PubMedGoogle Scholar
  • 4 Barker E L, Blakely R D. Norepinephrine and serotonin transporters. Molecular targets of antidepressant drugs. In: Bloom FE, Kupfer DJ (editors) Psychopharmacology. The fourth generation of progress. New York; Raven Press 1995: 321-333
    Google Scholar
  • 5 Bel N, Artigas F. In vivo effects of simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function: Microdialysis studies.  J Pharmacol Exp Ther. 1996;  278 1064-1072
    PubMedGoogle Scholar
  • 6 Berendsen H HG, Jenck F, Broekkamp C LE. Selective activation of 5-HT1A receptors induces lower lip retraction in the rat.  Pharmacol Biochem Behav. 1989;  33 821-827
    CrossrefPubMedGoogle Scholar
  • 7 Bhattacharya S K, Chakrabarti A, Chatterjee S S. Activity profiles of two hyperforin-containing hypericum extracts in behavioral models.  Pharmacopsychiatry. 1998;  31 ( Suppl 1) 22-29
    PubMedGoogle Scholar
  • 8 Biegon A, Israeli M. Regionally selective increases in beta-adrenergic receptor density in the brains of suicide victims.  Brain Res. 1988;  442 199-203
    CrossrefPubMedGoogle Scholar
  • 9 Bunney W E, Garland-Bunney B, Patel S B. Biological markers in depression.  Psychopathology. 1986;  19 72-78
    PubMedGoogle Scholar
  • 10 Butterweck V, Petereit F, Winterhoff H, Nahrstedt A. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test.  Planta Med. 1998;  64 291-294
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Butterweck V, Wall A, Lieflander-Wulf U, Winterhoff H, Nahrstedt A. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity.  Pharmacopsychiatry. 1997;  30 ( Suppl 2) 117-124
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Charney D S. Monoamine dysfunction and the pathophysiology and treatment of depression.  J Clin Psychiatry. 1998;  59 11-14
    PubMedGoogle Scholar
  • 13 Chatterjee S S, Bhattacharya S K, Wonnemann M, Singer A, Müller W E. Hyperforin as a possible antidepressant component of hypericum extracts.  Life Sci. 1998;  63 499-510
    CrossrefPubMedGoogle Scholar
  • 14 Coppen A. The biochemistry of affective disorders.  Br J Psychiatry. 1967;  113 1237-1264
    CrossrefPubMedGoogle Scholar
  • 15 Cott J M. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract.  Pharmacopsychiatry. 1997;  30 ( Suppl 2) 108-112
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Crespi D, Mennini T, Gobbi M. Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p- chloroamphetamine and (+)-fenfluramine.  Br J Pharmacol. 1997;  121 1735-1743
    PubMedGoogle Scholar
  • 17 Daniel W, Adamus A, Melzacka M, Szymura J. The route of administration of imipramine as a factor affecting formation of its metabolite desipramine.  J Pharm Pharmacol. 1982;  34 678-680
    PubMedGoogle Scholar
  • 18 Daniel W, Adamus A, Melzacka M, Szymura J, Vetulani J. Cerebral pharmacokinetics of imipramine in rats after single and multiple dosages.  Naunyn Schmiedebergs Arch Pharmacol. 1981;  317 209-213
    CrossrefPubMedGoogle Scholar
  • 19 Daniel W, Melzacka M. A comparative study on desipramine pharmacokinetics in the rat brain after administration of desipramine or imipramine.  J Pharm Pharmacol. 1992;  44 429-432
    PubMedGoogle Scholar
  • 20 Daws L C, Lopez R, Frazer A. Effects of antidepressant treatment on inhibitory avoidance behavior and amygdaloid beta-adrenoceptors in rats.  Neuropsychopharmacology. 1998a;  19 300-313
    CrossrefPubMedGoogle Scholar
  • 21 Daws L C, Toney G M, Gerhardt G A, Frazer A. In vivo chronoamperometric measures of extracellular serotonin clearance in rat dorsal hippocampus: contribution of serotonin and norepinephrine transporters.  J Pharmacol Exp Ther. 1998b;  286 967-976
    PubMedGoogle Scholar
  • 22 De Paermentier F, Cheetham S C, Crompton M R, Katona C L, Horton R W. Brain beta-adrenoceptor binding sites in antidepressant-free depressed suicide victims.  Brain Res. 1990;  525 71-77
    CrossrefPubMedGoogle Scholar
  • 23 De Paermentier F, Crompton M R, Katona C L, Horton R W. beta-Adrenoceptors in brain and pineal from depressed suicide victims.  Pharmacol Toxicol. 1992;  71 86-95
    PubMedGoogle Scholar
  • 24 De Vry J, Maurel S, Schreiber R, de Beun R, Jentzsch K R. Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism.  Eur Neuropsychopharmacol. 1999;  9 461-468
    CrossrefPubMedGoogle Scholar
  • 25 Decker M W, Curzon P, Brioni J D. Influence of separate and combined septal and amygdala lesions on memory, acoustic startle, anxiety, and locomotor activity in rats.  Neurobiol Learn Mem. 1995;  64 156-168
    CrossrefPubMedGoogle Scholar
  • 26 Decker M W, Gill T M, McGaugh J L. Concurrent muscarinic and beta-adrenergic blockade in rats impairs place-learning in a water maze and retention of inhibitory avoidance.  Brain Res. 1990;  513 81-85
    CrossrefPubMedGoogle Scholar
  • 27 Duncan G E, Paul I A, Breese G R. Neuroanatomical differences in the rate of beta-adrenergic receptor adaptation after repeated treatment with imipramine.  Psychopharmacol Bull. 1993;  29 401-407
    PubMedGoogle Scholar
  • 28 Fritze J. The adrenergic-cholinergic imbalance hypothesis of depression: a review and a perspective.  Rev Neurosci. 1993;  4 63-93
    PubMedGoogle Scholar
  • 29 Fujii T, Ohba S, Nakai K, Fujimoto K, Suzuki T, Kawashima K. Enhancement of the serotonin-mediated acetylcholine release by repeated desmethylimipramine treatment in the hippocampus of freely moving rats.  Jpn J Pharmacol. 1999;  80 303-309
    CrossrefPubMedGoogle Scholar
  • 30 Gallagher M, Chiba A A. The amygdala and emotion.  Curr Opin Neurobiol. 1996;  6 221-227
    CrossrefPubMedGoogle Scholar
  • 31 Gallagher M, Kapp B S, Musty R E, Driscoll P A. Memory formation: evidence for a specific neurochemical system in the amygdala.  Science. 1977;  198 423-425
    PubMedGoogle Scholar
  • 32 Gambarana C, Ghiglieri O, Tolu P, De Montis M G, Giachetti D, Bombardelli E, Tagliamonte A. Efficacy of an Hypericum perforatum (St. John’s wort) extract in preventing and reverting a condition of escape deficit in rats.  Neuropsychopharmacology. 1999;  21 247-257
    CrossrefPubMedGoogle Scholar
  • 33 Golden R N, Potter W Z. Neurochemical and neuroendocrine dysregulation in affective disorders.  Psychiatr Clin North Am. 1986;  9 313-327
    PubMedGoogle Scholar
  • 34 Goodnick P J, Goldstein B J. Selective serotonin reuptake inhibitors in affective disorders - I. Basic pharmacology.  J Psychopharmacol. 1998;  12 S5-S20
    PubMedGoogle Scholar
  • 35 Grahame-Smith D G. Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.  J Neurochem. 1971;  18 1053-1066
    PubMedGoogle Scholar
  • 36 Gurguis G N, Turkka J, Laruelle M, Kleinman J, Linnoila M. Coupling efficiency of brain beta-adrenergic receptors to Gs protein in suicide, alcoholism and control subjects.  Psychopharmacology. 1999;  145 31-38
    CrossrefPubMedGoogle Scholar
  • 37 Izquierdo I, Medina J H. Memory formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structures.  Neurobiol Learn Mem. 1997;  68 285-316
    CrossrefPubMedGoogle Scholar
  • 38 Jacobs B L. An animal behavior model for studying central serotonergic synapses.  Life Sci. 1976;  19 777-785
    CrossrefPubMedGoogle Scholar
  • 39 Kaehler S T, Sinner C, Chatterjee S S, Philippu A. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus.  Neurosci Lett. 1999;  262 199-202
    CrossrefPubMedGoogle Scholar
  • 40 Kaufmann C A, Gillin J C, Hill B, O’Laughlin T, Phillips I, Kleinman J E, Wyatt R J. Muscarinic binding in suicides.  Psychiatry Res. 1984;  12 47-55
    CrossrefPubMedGoogle Scholar
  • 41 Kim H L, Streltzer J, Goebert D. St. John’s wort for depression: a meta-analysis of well-defined clinical trials.  J Nerv Ment Dis. 1999;  187 532-538
    CrossrefPubMedGoogle Scholar
  • 42 Kirk R E. Experimental design: Procedures for the behavioural sciences. Belmont, CA; Brooks/Cole 1968
    Google Scholar
  • 43 Lavond D G, Kim J J, Thompson R F. Mammalian brain substrates of aversive classical conditioning.  Annu Rev Psychol. 1993;  44 317-342
    CrossrefPubMedGoogle Scholar
  • 44 Ledoux J E, Müller J. Emotional memory and psychopathology.  Philos Trans R Soc Lond B Biol Sci. 1997;  352 1719-1726
    PubMedGoogle Scholar
  • 45 Lester H A, Mager S, Quick M W, Corey J L. Permeation properties of neurotransmitter transporters.  Annu Rev Pharmacol Toxicol. 1994;  34 219-249
    CrossrefPubMedGoogle Scholar
  • 46 Maj J, Melzacka M, Mogilnicka E, Daniel W. Different pharmacokinetic and pharmacological effects following acute and chronic treatment with imipramine.  J Neural Transm. 1982;  54 219-228
    CrossrefPubMedGoogle Scholar
  • 47 Mann J J, Halper J P, Wilner P J, Sweeney J A, Mieczkowski T A, Chen J S, Stokes P E, Brown R P. Subsensitivity of adenylyl cyclase-coupled receptors on mononuclear leukocytes from drug-free inpatients with a major depressive episode.  Biol Psychiatry. 1997;  42 859-870
    CrossrefPubMedGoogle Scholar
  • 48 Meyerson L R, Wennogle L P, Abel M S, Coupet J, Lippa A S, Rauh C E, Beer B. Human brain receptor alterations in suicide victims.  Pharmacol Biochem Behav. 1982;  17 159-163
    CrossrefPubMedGoogle Scholar
  • 49 Misane I, Ögren S O. Multiple 5-HT receptors in passive avoidance: comparative studies of p-chloroamphetamine and 8-OH-DPAT.  Neuropsychopharmacology. 2000;  22 168-190
    CrossrefPubMedGoogle Scholar
  • 50 Müller W E, Rolli M, Schafer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity.  Pharmacopsychiatry. 1997;  30 ( Suppl 2) 102-107
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Müller W E, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract.  Pharmacopsychiatry. 1998;  31 ( Suppl 1) 16-21
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Mulrow C D, Williams J W, Trivedi M, Chiquette E, Aguilar C, Cornell J E, Badgett R, Noel P H, Lawrence V, Lee S, Luther M, Ramirez G, Richardson W S, Stamm K. Treatment of depression - newer pharmacotherapies.  Psychopharmacol Bull. 1998;  34 409-795
    PubMedGoogle Scholar
  • 53 Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L.  Pharmacopsychiatry. 1997;  30 ( Suppl 2) 129-134
    PubMedGoogle Scholar
  • 54 Ögren S O. Central serotonin neurones in avoidance learning: interactions with noradrenaline and dopamine neurones.  Pharmacol Biochem Behav. 1985a;  23 107-123
    CrossrefPubMedGoogle Scholar
  • 55 Ögren S O. Evidence for a role of brain serotonergic neurotransmission in avoidance learning.  Acta Physiol Scand Suppl. 1985b;  544 1-71
    PubMedGoogle Scholar
  • 56 Okpanyi S N, Weischer M L. Animal experiments on the psychotropic action of a Hypericum extract.  Arzneimittelforschung. 1987;  37 10-13
    PubMedGoogle Scholar
  • 57 Ordway G A, Gambarana C, Tejani-Butt S M, Areso P, Hauptmann M, Frazer A. Preferential reduction of binding of 125I-iodopindolol to beta-1 adrenoceptors in the amygdala of rat after antidepressant treatments.  J Pharmacol Exp Ther. 1991;  257 681-690
    PubMedGoogle Scholar
  • 58 Plenge P, Mellerup E T, Laursen H. Affinity modulation of [3H]imipramine, [3H]paroxetine and [3H]citalopram binding to the 5-HT transporter from brain and platelets.  Eur J Pharmacol. 1991;  206 243-250
    PubMedGoogle Scholar
  • 59 van Praag H M. Could some depressions be conditioned by derailment of serotonin/cortisol interaction?. In: Palomo T, Beninger RJ, Archer T (editors) Interactive monoaminergic disorders. Madrid; Editorial Sintesis 1999: 91-105
    Google Scholar
  • 60 Rehavi M, Maayani S, Sokolovsky M. Tricyclic antidepressants as antimuscarinic drugs: in vivo and in vitro studies.  Biochem Pharmacol. 1977;  26 1559-1567
    CrossrefPubMedGoogle Scholar
  • 61 Richelson E. Cholinergic transmission. In: Bloom FE, Kupfer DJ (editors) Psychopharmacology. The fourth generation of progress. New York; Raven Press 1995: 125-134
    Google Scholar
  • 62 Singer A, Wonnemann M, Müller W E. Hyperforin, a major antidepressant constituent of St. John’s Wort, inhibits serotonin uptake by elevating free intracellular Na+1.  J Pharmacol Exp Ther. 1999;  290 1363-1368
    PubMedGoogle Scholar
  • 63 Snyder S H, Yamamura H I. Antidepressants and the muscarinic acetylcholine receptor.  Arch Gen Psychiatry. 1977;  34 236-239
    PubMedGoogle Scholar
  • 64 Stahl S M. Basic psychopharmacology of antidepressants. Part 1: Antidepressants have seven distinct mechanisms of action.  J Clin Psychiatry. 1998;  59 5-14
    PubMedGoogle Scholar
  • 65 Stevinson C, Ernst E. Hypericum for depression. An update of the clinical evidence.  Eur Neuropsychopharmacol. 1999;  9 501-505
    CrossrefPubMedGoogle Scholar
  • 66 Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H. Inhibition of monoamine oxidase by hypericin.  Planta Med. 1984;  50 272-274
    Article in Thieme ConnectPubMedGoogle Scholar
  • 67 Trulson M E, Jacobs B L. Behavioral evidence for the rapid release of CNS serotonin by PCA and fenfluramine.  Eur J Pharmacol. 1976;  36 149-154
    CrossrefPubMedGoogle Scholar

Dr. Ilga Misane

Department of Molecular Neuroendocrinology
Max Planck Institute for Experimental Medicine

Hermann Rein Strasse 3

37075 Goettingen

Germany

Phone: +49-551-3899-400

Fax: +49-551-3899-439

Email: Misane@mail.em.mpg.de

      >